4,654 research outputs found

    Dual Ventricular Response or 1 : 2 Atrioventricular Conduction in Dual Atrioventricular Nodal Physiology

    Get PDF
    Dual ventricular response to a single supraventricular impulse is an interesting possibility in the presence of dual atrioventricular nodal physiology. Double His bundle and ventricular responses to a single atrial impulse caused by a simultaneous fast and slow pathway conduction is the hallmark of this condition. One of the earliest descriptions of simultaneous conduction through both atrioventricular (AV) nodal pathways was by Csapo G1, who described various electrocardiographic patterns due to simultaneous conduction through dual AV nodal pathways. Activation through triple AV nodal pathways has also been described2,3. In one case2 an atrial impulse evoked double ventricular response due to simultaneous activation of the slow and fast pathway. The next impulse activated the ventricles through the intermediate pathway, The net result was a narrow QRS tachycardia with irregular RR intervals. In another case3 an incessant form of complex supraventricular tachycardia was noted, with simultaneous conduction over multiple AV nodal pathways. The tachycardia was successfully treated by ablation of intermediate and slow pathways. Over 20 cases non-reentrant supraventricular tachycardia with 1:2 AV conduction during sinus rhythm has been described in literature so far4-1

    IT-ENABLED KNOWLEDGE MANAGEMENT IN HEALTHCARE DELIVERY: THE CASE OF EMERGENCY CARE

    Get PDF
    IT is viewed as integral to achieving substantial quality and efficiency improvements in U.S. healthcare delivery and management. A key idea behind these suggestions is the use of IT to support knowledge management to enhance and facilitate evidence-based clinical decisionmaking. Yet, it is not clear to what extent IT-enabled knowledge management systems will be effective for physicians who make complex clinical decisions under time pressure and high degree of uncertainty. To address this gap, we are conducting a field study to examine the impact of ITenabled knowledge management systems in an emergency department at a major university hospital in the Southeast region of the US. The preliminary results of our analyses show that the use of IT-enabled knowledge application tools indeed influence the healthcare professional’s clinical decision-making behaviors, which in turn influence the outcome of patient care

    Association Between Genetic Variants on Chromosome 15q25 Locus and Objective Measures of Tobacco Exposure

    Get PDF
    Background: Two single-nucleotide polymorphisms, rs1051730 and rs16969968, located within the nicotinic acetylcholine receptor gene cluster on chromosome 15q25 locus, are associated with heaviness of smoking, risk for lung cancer, and other smoking-related health outcomes. Previous studies have typically relied on self-reported smoking behavior, which may not fully capture interindividual variation in tobacco exposure. / Methods: We investigated the association of rs1051730 and rs16969968 genotype (referred to as rs1051730–rs16969968, because these are in perfect linkage disequilibrium and interchangeable) with both self-reported daily cigarette consumption and biochemically measured plasma or serum cotinine levels among cigarette smokers. Summary estimates and descriptive statistical data for 12 364 subjects were obtained from six independent studies, and 2932 smokers were included in the analyses. Linear regression was used to calculate the per-allele association of rs1051730–rs16969968 genotype with cigarette consumption and cotinine levels in current smokers for each study. Meta-analysis of per-allele associations was conducted using a random effects method. The likely resulting association between genotype and lung cancer risk was assessed using published data on the association between cotinine levels and lung cancer risk. All statistical tests were two-sided. / Results: Pooled per-allele associations showed that current smokers with one or two copies of the rs1051730–rs16969968 risk allele had increased self-reported cigarette consumption (mean increase in unadjusted number of cigarettes per day per allele = 1.0 cigarette, 95% confidence interval [CI] = 0.57 to 1.43 cigarettes, P = 5.22 × 10−6) and cotinine levels (mean increase in unadjusted cotinine levels per allele = 138.72 nmol/L, 95% CI = 97.91 to 179.53 nmol/L, P = 2.71 × 10−11). The increase in cotinine levels indicated an increased risk of lung cancer with each additional copy of the rs1051730–rs16969968 risk allele (per-allele odds ratio = 1.31, 95% CI = 1.21 to 1.42). / Conclusions: Our data show a stronger association of rs1051730–rs16969968 genotype with objective measures of tobacco exposure compared with self-reported cigarette consumption. The association of these variants with lung cancer risk is likely to be mediated largely, if not wholly, via tobacco exposure

    Recurrent herpes zoster in the Shingles Prevention Study: Are second episodes caused by the same varicella-zoster virus strain?

    Get PDF
    Herpes zoster (HZ) is caused by reactivation of varicella zoster virus (VZV) that established latency in sensory and autonomic neurons during primary infection. In the Shingles Prevention Study (SPS), a large efficacy trial of live attenuated Oka/Merck zoster vaccine (ZVL), PCR-confirmed second episodes of HZ occurred in two of 660 placebo and one of 321 ZVL recipients with documented HZ during a mean follow-up of 3.13 years. An additional two ZVL recipients experienced a second episode of HZ in the Long-Term Persistence Substudy. All episodes of HZ were caused by wild-type VZV. The first and second episodes of HZ occurred in different dermatomes in each of these five participants, with contralateral recurrences in two. Time between first and second episodes ranged from 12 to 28 months. One of the five participants, who was immunocompetent on study enrollment, was immunocompromised at the onset of his first and second episodes of HZ. VZV DNA isolated from rash lesions from the first and second episodes of HZ was used to sequence the full-length VZV genomes. For the unique-sequence regions of the VZV genome, we employed target enrichment of VZV DNA, followed by deep sequencing. For the reiteration regions, we used PCR amplification and Sanger sequencing. Our analysis and comparison of the VZV genomes from the first and second episodes of HZ in each of the five participants indicate that both episodes were caused by the same VZV strain. This is consistent with the extraordinary stability of VZV during the replication phase of varicella and the subsequent establishment of latency in sensory ganglia throughout the body. Our observations also indicate that VZV is stable during the persistence of latency and the subsequent reactivation and replication that results in HZ

    Pitfalls of haplotype phasing from amplicon-based long-read sequencing

    Get PDF
    This is the final version. Available on open access from Nature Research via the DOI in this recordThe long-read sequencers from Pacific Bioscience (PacBio) and Oxford Nanopore Technologies (ONT) offer the opportunity to phase mutations multiple kilobases apart directly from sequencing reads. In this study, we used long-range PCR with ONT and PacBio sequencing to phase two variants 9 kb apart in the RET gene. We also re-analysed data from a recent paper which had apparently successfully used ONT to phase clinically important haplotypes at the CYP2D6 and HLA loci. From these analyses, we demonstrate PCR-chimera formation during PCR amplification and reference alignment bias are pitfalls that need to be considered when attempting to phase variants using amplicon-based long-read sequencing technologies. These methodological pitfalls need to be avoided if the opportunities provided by long-read sequencers are to be fully exploited.Wellcome Trus

    SavvyCNV: Genome-wide CNV calling from off-target reads

    Get PDF
    This is the uncorrected proof. The final version is available on open access from Public Library of Science via the DOI in this recordData Availability: The SavvyCNV tool and the code used to run the benchmarking comparisons are freely available on github. The tool is available at https://github.com/rdemolgen/SavvySuite. The code used to run the benchmarking comparisons is available at: https://github.com/exeter-matthew-wakeling/SavvyCNV_benchmarking. Our study uses the ICR96 data set for benchmarking, which is publicly available and can be accessed through the European-Genome phenome Archive (EGA) under the accession number EGAS00001002428. The dataset of 2591 samples referred to the molecular genetics department at the Royal Devon and Exeter Hospital for genetic testing cannot be shared due to patient confidentiality issues, as the genotype data could be used to identify individuals and so cannot be made openly available. Requests for access to the anonymised data by researchers will be considered following an application to the Genetic Beta Cell Research Bank (https://www.diabetesgenes.org/current-research/genetic-beta-cell-research-bank/) with proposals reviewed by the Genetic Data Access Committee.Identifying copy number variants (CNVs) can provide diagnoses to patients and provide important biological insights into human health and disease. Current exome and targeted sequencing approaches cannot detect clinically and biologically-relevant CNVs outside their target area. We present SavvyCNV, a tool which uses off-target read data from exome and targeted sequencing data to call germline CNVs genome-wide. Up to 70% of sequencing reads from exome and targeted sequencing fall outside the targeted regions. We have developed a new tool, SavvyCNV, to exploit this 'free data' to call CNVs across the genome. We benchmarked SavvyCNV against five state-of-the-art CNV callers using truth sets generated from genome sequencing data and Multiplex Ligation-dependent Probe Amplification assays. SavvyCNV called CNVs with high precision and recall, outperforming the five other tools at calling CNVs genome-wide, using off-target or on-target reads from targeted panel and exome sequencing. We then applied SavvyCNV to clinical samples sequenced using a targeted panel and were able to call previously undetected clinically-relevant CNVs, highlighting the utility of this tool within the diagnostic setting. SavvyCNV outperforms existing tools for calling CNVs from off-target reads. It can call CNVs genome-wide from targeted panel and exome data, increasing the utility and diagnostic yield of these tests. SavvyCNV is freely available at https://github.com/rdemolgen/SavvySuite.Medical Research Council (MRC)Research EnglandDiabetes U

    REVEL Is Better at Predicting Pathogenicity of Loss-of-Function than Gain-of-Function Variants

    Get PDF
    This is the final version. Available on open access from Hindawi via the DOI in this recordData Availability: The list of variants used in this study are included in Supplementary Table 1.In silico predictive tools can help determine the pathogenicity of variants. The 2015 American College of Medical Genetics and Genomics (ACMG) guidelines recommended that scores from these tools can be used as supporting evidence of pathogenicity. A subsequent publication by the ClinGen Sequence Variant Interpretation Working Group suggested that high scores from some tools were sufficiently predictive to be used as moderate or strong evidence of pathogenicity. REVEL is a widely used metapredictor that uses the scores of 13 individual in silico tools to calculate the pathogenicity of missense variants. Its ability to predict missense pathogenicity has been assessed extensively; however, no study has previously tested whether its performance is affected by whether the missense variant acts via a loss-of-function (LoF) or gain-of-function (GoF) mechanism. We used a highly curated dataset of 66 confirmed LoF and 65 confirmed GoF variants to evaluate whether this affected the performance of REVEL. 98% of LoF and 100% of GoF variants met the author-recommended REVEL threshold of 0.5 for pathogenicity, while 89% of LoF and 88% of GoF variants exceeded the 0.75 threshold. However, while 55% of LoF variants met the threshold recommended for a REVEL score to count as strong evidence of pathogenicity from the ACMG guidelines (0.932), only 35% of GoF variants met this threshold (). GoF variants are therefore less likely to receive the highest REVEL scores which would enable the REVEL score to be used as strong evidence of pathogenicity. This has implications for classification with the ACMG guidelines as GoF variants are less likely to meet the criteria for pathogenicity. P = 0.0352 ). GoF variants are therefore less likely to receive the highest REVEL scores which would enable the REVEL score to be used as strong evidence of pathogenicity. This has implications for classification with the ACMG guidelines as GoF variants are less likely to meet the criteria for pathogenicity.Wellcome TrustResearch EnglandNational Institute for Health and Care Research (NIHR

    Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking status to influence body mass index

    Get PDF
    Cigarette smoking is associated with lower body mass index (BMI), and a commonly cited reason for unwillingness to quit smoking is a concern about weight gain. Common variation in the CHRNA5-CHRNA3-CHRNB4 gene region (chromosome 15q25) is robustly associated with smoking quantity in smokers, but its association with BMI is unknown. We hypothesized that genotype would accurately reflect smoking exposure and that, if smoking were causally related to weight, it would be associated with BMI in smokers, but not in never smokers
    corecore